[{"id":"beb344ab-95cf-420e-8ccd-b61bc4f7a537","acronym":"","url":"https://clinicaltrials.gov/study/NCT07097363","created_at":"2025-08-02T14:05:17.045Z","updated_at":"2025-08-02T14:05:17.045Z","phase":"Phase 2","brief_title":"Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT07097363","lead_sponsor":"University of Washington","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 05/31/2030","primary_completion_date":" 05/31/2030","study_txt":" Completion: 05/31/2030","study_completion_date":" 05/31/2030","last_update_posted":"2025-07-31"},{"id":"1394e99e-c38f-44e4-ab4d-aee1d10301bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05507541","created_at":"2022-08-19T17:10:01.039Z","updated_at":"2025-02-25T12:28:56.881Z","phase":"Phase 2","brief_title":"TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT05507541","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1 • ALK • BCL2 • BCL6 • IRF4","pipe":" | ","alterations":" ALK positive","tags":["PD-L1 • ALK • BCL2 • BCL6 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • maplirpacept (TTI-622) • ontorpacept (PF-07901800)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-24"},{"id":"2224e4ab-560d-46f1-b752-7b1d2154770f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04240808","created_at":"2021-01-18T20:37:11.481Z","updated_at":"2025-02-25T12:37:29.775Z","phase":"Phase 1","brief_title":"Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)","source_id_and_acronym":"NCT04240808","lead_sponsor":"University of Colorado, Denver","biomarkers":" CD19","pipe":" | ","alterations":" CD19 positive","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UCD19 CAR T Cells"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/17/2020","start_date":" 07/17/2020","primary_txt":" Primary completion: 03/24/2023","primary_completion_date":" 03/24/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-24"},{"id":"736082c4-cb8f-4038-ae24-2c9486718043","acronym":"BP41072","url":"https://clinicaltrials.gov/study/NCT04077723","created_at":"2021-01-18T19:58:08.759Z","updated_at":"2025-02-25T13:39:56.985Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT04077723 - BP41072","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD20 expression • CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • englumafusp alfa (RG6076)"],"overall_status":"Recruiting","enrollment":" Enrollment 498","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-21"},{"id":"d1651a97-e0b7-453b-880d-d4d563121330","acronym":"","url":"https://clinicaltrials.gov/study/NCT06834373","created_at":"2025-02-25T13:57:53.594Z","updated_at":"2025-02-25T13:57:53.594Z","phase":"Phase 2","brief_title":"Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy","source_id_and_acronym":"NCT06834373","lead_sponsor":"Mayo Clinic","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/03/2025","start_date":" 03/03/2025","primary_txt":" Primary completion: 03/03/2027","primary_completion_date":" 03/03/2027","study_txt":" Completion: 03/03/2027","study_completion_date":" 03/03/2027","last_update_posted":"2025-02-20"},{"id":"ea26acb5-1d9c-43f2-bde5-b6e08ca13bd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554939","created_at":"2022-09-26T14:56:16.908Z","updated_at":"2025-02-25T14:09:09.767Z","phase":"Phase 1/2","brief_title":"Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL","source_id_and_acronym":"NCT05554939","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" CD19 positive • Chr t(11;14)","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Mustargen (mechlorethamine)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/11/2022","start_date":" 12/11/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-19"},{"id":"796304d3-46d7-4eb0-aa64-9c9bbe7b7955","acronym":"Pola-R-ICE","url":"https://clinicaltrials.gov/study/NCT04833114","created_at":"2021-04-06T11:55:24.930Z","updated_at":"2025-02-25T14:15:54.989Z","phase":"Phase 3","brief_title":"Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)","source_id_and_acronym":"NCT04833114 - Pola-R-ICE","lead_sponsor":"GWT-TUD GmbH","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 306","initiation":"Initiation: 04/30/2021","start_date":" 04/30/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-18"},{"id":"8058c94b-0d21-42b2-b6cf-b07e05abfcb1","acronym":"PRO00037171","url":"https://clinicaltrials.gov/study/NCT04186520","created_at":"2021-07-05T17:26:53.958Z","updated_at":"2025-02-25T14:15:30.805Z","phase":"Phase 1/2","brief_title":"CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies","source_id_and_acronym":"NCT04186520 - PRO00037171","lead_sponsor":"Medical College of Wisconsin","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CAR-20/19-T Cells"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/18/2020","start_date":" 05/18/2020","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-18"},{"id":"dc690118-6ca4-4812-9ba9-2f56494fb793","acronym":"GO29781","url":"https://clinicaltrials.gov/study/NCT02500407","created_at":"2021-01-18T12:03:14.142Z","updated_at":"2025-02-25T14:06:51.320Z","phase":"Phase 1/2","brief_title":"A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)","source_id_and_acronym":"NCT02500407 - GO29781","lead_sponsor":"Genentech, Inc.","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 713","initiation":"Initiation: 09/15/2015","start_date":" 09/15/2015","primary_txt":" Primary completion: 05/21/2024","primary_completion_date":" 05/21/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-18"},{"id":"90ac22c8-dcce-478e-af97-ed4ef0a3b357","acronym":"","url":"https://clinicaltrials.gov/study/NCT04665765","created_at":"2021-01-19T20:43:36.698Z","updated_at":"2025-02-25T14:08:04.780Z","phase":"Phase 2","brief_title":"Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT04665765","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • cyclophosphamide • ifosfamide • etoposide IV • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 01/18/2021","start_date":" 01/18/2021","primary_txt":" Primary completion: 07/26/2022","primary_completion_date":" 07/26/2022","study_txt":" Completion: 07/08/2025","study_completion_date":" 07/08/2025","last_update_posted":"2025-02-17"},{"id":"2bded2d4-47b6-42ef-85b2-a3d47668df11","acronym":"BELINDA","url":"https://clinicaltrials.gov/study/NCT03570892","created_at":"2021-01-18T17:34:21.137Z","updated_at":"2025-02-25T14:39:57.185Z","phase":"Phase 3","brief_title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03570892 - BELINDA","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Kymriah (tisagenlecleucel-T) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 331","initiation":"Initiation: 05/07/2019","start_date":" 05/07/2019","primary_txt":" Primary completion: 05/06/2021","primary_completion_date":" 05/06/2021","study_txt":" Completion: 02/14/2026","study_completion_date":" 02/14/2026","last_update_posted":"2025-02-14"},{"id":"f3d0b4ce-a825-4e88-abe6-0a2852f91550","acronym":"SUNMO","url":"https://clinicaltrials.gov/study/NCT05171647","created_at":"2021-12-29T14:53:50.426Z","updated_at":"2025-02-25T14:41:08.199Z","phase":"Phase 3","brief_title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT05171647 - SUNMO","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • oxaliplatin • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 04/25/2022","start_date":" 04/25/2022","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-14"},{"id":"61d56240-acd7-4036-be44-40ad727ab77a","acronym":"A051701","url":"https://clinicaltrials.gov/study/NCT03984448","created_at":"2021-01-18T19:35:47.901Z","updated_at":"2025-02-25T15:11:12.787Z","phase":"Phase 2/3","brief_title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","source_id_and_acronym":"NCT03984448 - A051701","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 363","initiation":"Initiation: 10/22/2019","start_date":" 10/22/2019","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-02-13"},{"id":"d02f7b2d-1c37-4780-a6b7-7db1aff0b46d","acronym":"PBCAR0191-01","url":"https://clinicaltrials.gov/study/NCT03666000","created_at":"2021-01-18T17:59:15.398Z","updated_at":"2025-02-25T15:10:55.408Z","phase":"Phase 1","brief_title":"Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL","source_id_and_acronym":"NCT03666000 - PBCAR0191-01","lead_sponsor":"Imugene Limited","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • azercabtagene zapreleucel (PBCAR0191) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 129","initiation":"Initiation: 03/11/2019","start_date":" 03/11/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-13"},{"id":"8e3b627a-4aef-4d49-a1cb-f09137cdb6c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06536049","created_at":"2025-02-25T15:21:55.068Z","updated_at":"2025-02-25T15:21:55.068Z","phase":"Phase 1/2","brief_title":"Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT06536049","lead_sponsor":"Yazeed Sawalha","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Epkinly (epcoritamab-bysp)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-12"},{"id":"c0f4d14f-2257-447f-847c-ebe3a10d55e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01087294","created_at":"2023-05-20T02:04:59.343Z","updated_at":"2025-02-25T15:32:08.685Z","phase":"Phase 1","brief_title":"Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT01087294","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"],"overall_status":"Completed","enrollment":" Enrollment 85","initiation":"Initiation: 08/04/2010","start_date":" 08/04/2010","primary_txt":" Primary completion: 03/08/2024","primary_completion_date":" 03/08/2024","study_txt":" Completion: 04/02/2024","study_completion_date":" 04/02/2024","last_update_posted":"2025-02-11"},{"id":"2dc4eb4c-eda6-4d7f-bf25-c974b4ee8106","acronym":"CO43805","url":"https://clinicaltrials.gov/study/NCT05169515","created_at":"2021-12-27T15:54:16.180Z","updated_at":"2025-02-25T15:27:09.973Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05169515 - CO43805","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb) • iberdomide (CC-220) • Columvi (glofitamab-gxbm) • golcadomide (CC-99282)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 03/07/2027","primary_completion_date":" 03/07/2027","study_txt":" Completion: 03/07/2029","study_completion_date":" 03/07/2029","last_update_posted":"2025-02-10"},{"id":"dba621d0-4a3a-4b6c-9b33-c48c7ade782a","acronym":"iMATRIX GLO","url":"https://clinicaltrials.gov/study/NCT05533775","created_at":"2022-09-09T15:55:02.207Z","updated_at":"2025-02-25T15:27:37.954Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05533775 - iMATRIX GLO","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD4","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 03/30/2027","primary_completion_date":" 03/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2025-02-10"},{"id":"ad314edd-2963-47ac-86cd-5f06a81ee36e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06005649","created_at":"2023-08-22T15:08:54.438Z","updated_at":"2025-02-25T16:33:37.494Z","phase":"Phase 1/2","brief_title":"Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT06005649","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" BCL2 • BCL6 • IL6 • CD22","pipe":" | ","alterations":" CD19 positive","tags":["BCL2 • BCL6 • IL6 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • HY004"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-07"},{"id":"52a20f08-fb55-44a8-b556-28ccbdd505e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05421663","created_at":"2022-06-16T15:00:08.321Z","updated_at":"2025-02-25T16:39:05.573Z","phase":"Phase 1","brief_title":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05421663","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prizloncabtagene autoleucel (JNJ-4496)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 08/12/2022","start_date":" 08/12/2022","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 12/29/2028","study_completion_date":" 12/29/2028","last_update_posted":"2025-02-06"},{"id":"7fd7343b-e00a-415f-aa0d-62ed50ea285e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02051257","created_at":"2021-01-18T09:25:59.407Z","updated_at":"2025-02-25T16:43:46.952Z","phase":"Phase 1","brief_title":"Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT02051257","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD28","pipe":" | ","alterations":" CD28 expression","tags":["CD28"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD28 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 CAR T cells"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 06/19/2014","start_date":" 06/19/2014","primary_txt":" Primary completion: 03/24/2025","primary_completion_date":" 03/24/2025","study_txt":" Completion: 03/24/2025","study_completion_date":" 03/24/2025","last_update_posted":"2025-02-06"},{"id":"95346b3d-9ef2-4e77-bfd1-0fdc5d0b84e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06707259","created_at":"2025-02-25T16:41:47.922Z","updated_at":"2025-02-25T16:41:47.922Z","phase":"Phase 1","brief_title":"Clinical Study of Cord Blood-derived IL-10 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL","source_id_and_acronym":"NCT06707259","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" IL10","pipe":"","alterations":" ","tags":["IL10"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-06"},{"id":"9a9ff008-2d0b-4d26-91f5-d8f2ec4ab9cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672251","created_at":"2023-01-05T14:58:29.816Z","updated_at":"2025-02-25T16:39:34.057Z","phase":"Phase 2","brief_title":"Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT05672251","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynlonta (loncastuximab tesirine-lpyl) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/02/2024","start_date":" 01/02/2024","primary_txt":" Primary completion: 04/22/2025","primary_completion_date":" 04/22/2025","study_txt":" Completion: 04/22/2025","study_completion_date":" 04/22/2025","last_update_posted":"2025-02-06"},{"id":"ad11f149-0ac3-4e5e-9a2c-090277fc61cc","acronym":"CRC-403","url":"https://clinicaltrials.gov/study/NCT05169489","created_at":"2021-12-27T15:54:15.732Z","updated_at":"2025-02-25T17:01:36.333Z","phase":"Phase 1/2","brief_title":"A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)","source_id_and_acronym":"NCT05169489 - CRC-403","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bbT369"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/24/2022","start_date":" 01/24/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-03"}]